DK1962886T4 - Stabile proteinformuleringer - Google Patents

Stabile proteinformuleringer Download PDF

Info

Publication number
DK1962886T4
DK1962886T4 DK06846683.8T DK06846683T DK1962886T4 DK 1962886 T4 DK1962886 T4 DK 1962886T4 DK 06846683 T DK06846683 T DK 06846683T DK 1962886 T4 DK1962886 T4 DK 1962886T4
Authority
DK
Denmark
Prior art keywords
protein formulations
stable protein
stable
formulations
protein
Prior art date
Application number
DK06846683.8T
Other languages
Danish (da)
English (en)
Other versions
DK1962886T3 (da
Inventor
Manisha M Dali
Charles E Dahlheim
Sunita Borsadia
Vijay H Naringrekar
Rajesh B Gandhi
Manoj Nerurkar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1962886(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DK1962886T3 publication Critical patent/DK1962886T3/da
Application granted granted Critical
Publication of DK1962886T4 publication Critical patent/DK1962886T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DK06846683.8T 2005-12-20 2006-12-19 Stabile proteinformuleringer DK1962886T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (2)

Publication Number Publication Date
DK1962886T3 DK1962886T3 (da) 2014-01-13
DK1962886T4 true DK1962886T4 (da) 2022-05-02

Family

ID=38057529

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06846683.8T DK1962886T4 (da) 2005-12-20 2006-12-19 Stabile proteinformuleringer

Country Status (24)

Country Link
US (1) US8476239B2 (enExample)
EP (1) EP1962886B2 (enExample)
JP (2) JP5247467B2 (enExample)
KR (1) KR101378194B1 (enExample)
CN (3) CN101378773B (enExample)
AR (2) AR058567A1 (enExample)
AU (1) AU2006330593B2 (enExample)
BR (1) BRPI0622256A2 (enExample)
CA (1) CA2634547C (enExample)
CL (1) CL2010000816A1 (enExample)
DK (1) DK1962886T4 (enExample)
EA (1) EA014232B1 (enExample)
ES (1) ES2436616T5 (enExample)
HR (1) HRP20131196T4 (enExample)
IL (1) IL192104A (enExample)
NO (1) NO347247B1 (enExample)
NZ (1) NZ569108A (enExample)
PE (1) PE20071063A1 (enExample)
PL (1) PL1962886T6 (enExample)
PT (1) PT1962886E (enExample)
RS (1) RS53127B2 (enExample)
SG (1) SG153832A1 (enExample)
TW (3) TW200738261A (enExample)
WO (1) WO2007076354A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN105435211A (zh) 2008-10-06 2016-03-30 三维肽胶株式会社 组织闭塞剂
EP2445616B1 (en) * 2009-06-23 2018-05-02 GE Healthcare Bio-Sciences AB Simulator device
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
EP2699258A4 (en) * 2011-04-15 2014-10-29 Us Sec Dep Of Health And Human Services AAV-mediated CTLA-4 gene transfer for the treatment of SJÖGREN SYNDROME
CA2833623A1 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012326170B2 (en) * 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
WO2014004780A1 (en) 2012-06-29 2014-01-03 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
EP2869903B1 (en) 2012-07-06 2018-11-28 3-D Matrix Ltd. Fill-finish process for peptide solutions
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
AU2013308470B2 (en) 2012-08-31 2017-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
DK3116896T3 (en) 2014-03-10 2019-03-18 3 D Matrix Ltd SELF-PREPARING PEPTIME COMPOSITIONS
ES3037364T3 (en) 2014-03-10 2025-10-01 3 D Matrix Ltd Sterilization and filtration of peptide compositions
US20170051059A1 (en) 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
WO2015164595A1 (en) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20180200325A1 (en) 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3347031T3 (da) * 2015-09-11 2021-04-26 Nutrition & Biosciences Usa 1 Llc Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
WO2019123427A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
CN112512561A (zh) * 2018-05-25 2021-03-16 雷迪博士实验室有限公司 稳定的融合蛋白制剂
CN112512562A (zh) * 2018-05-25 2021-03-16 雷迪博士实验室有限公司 CTLA4-Ig融合蛋白制剂
EP3813791A2 (en) * 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
EP3814492A4 (en) * 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
CN113508129B (zh) 2019-01-15 2025-02-18 法国国家健康和医学研究院 突变的白介素-34(il-34)多肽及其在治疗中的用途
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
WO2022162704A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
BR112023019385A2 (pt) 2021-03-23 2023-12-05 King S College London Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
KR20250054810A (ko) * 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁（杭州）生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
TWI328614B (en) 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2618068C (en) * 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations

Also Published As

Publication number Publication date
CN101584858A (zh) 2009-11-25
AU2006330593B2 (en) 2012-07-26
ES2436616T5 (es) 2022-05-27
EP1962886B2 (en) 2022-02-23
JP5538309B2 (ja) 2014-07-02
US8476239B2 (en) 2013-07-02
WO2007076354A2 (en) 2007-07-05
EP1962886A2 (en) 2008-09-03
RS53127B (sr) 2014-06-30
DK1962886T3 (da) 2014-01-13
US20100166774A1 (en) 2010-07-01
AR058567A1 (es) 2008-02-13
EA200801570A1 (ru) 2008-12-30
KR101378194B1 (ko) 2014-03-27
CN101378773B (zh) 2013-03-13
CL2010000816A1 (es) 2011-02-11
NO20082628L (no) 2008-07-15
PL1962886T3 (pl) 2014-03-31
TW200738261A (en) 2007-10-16
NZ569108A (en) 2011-09-30
RS53127B2 (sr) 2022-06-30
PT1962886E (pt) 2014-01-07
BRPI0622256A2 (pt) 2011-08-09
CN101822820A (zh) 2010-09-08
AU2006330593A1 (en) 2007-07-05
HRP20131196T4 (hr) 2022-06-10
CN101378773A (zh) 2009-03-04
AR097561A2 (es) 2016-03-23
BRPI0620186A2 (pt) 2010-07-06
CA2634547A1 (en) 2007-07-05
TW201008596A (en) 2010-03-01
PL1962886T6 (pl) 2023-03-13
HK1114568A1 (en) 2008-11-07
CA2634547C (en) 2016-10-11
IL192104A (en) 2015-01-29
SG153832A1 (en) 2009-07-29
KR20080078070A (ko) 2008-08-26
EA014232B1 (ru) 2010-10-29
IL192104A0 (en) 2008-12-29
JP2009524595A (ja) 2009-07-02
WO2007076354A3 (en) 2007-08-16
TWI393575B (zh) 2013-04-21
TW201008595A (en) 2010-03-01
HRP20131196T1 (hr) 2014-01-31
PE20071063A1 (es) 2007-10-24
JP5247467B2 (ja) 2013-07-24
NO347247B1 (no) 2023-07-31
EP1962886B1 (en) 2013-10-16
ES2436616T3 (es) 2014-01-03
JP2011246470A (ja) 2011-12-08

Similar Documents

Publication Publication Date Title
DK1962886T3 (da) Stabile proteinformuleringer
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
NO20075628L (no) Farmasøytiske formuleringer
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DE502006006338D1 (de) Ächen
DK1928882T3 (da) (s)-n-methylnaltrexon
EP1857091A4 (en) COSMETIC
EP1951275A4 (en) COMPOSITION AGAINST ADIPOSITAS
DK1965646T3 (da) Herbicid sammensætning
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
DK1804871T3 (da) Forbedret mellemstykke
DE602006012066D1 (de) Daraus
EP1893244A4 (en) AGENTS FOR IMAGING
EP1875926A4 (en) Stable emulsion composition
ATE423466T1 (de) Herbizidzusammensetzung
DK1809660T3 (da) Thymus-specifikt protein
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
DE502006005207D1 (de) Bauteilen
EP1750718A4 (en) FORMULATIONS OF ACYCLOVIR
DE602006000179D1 (de) Schaltverstärker
DE502006006589D1 (de) Teils
NO20052428D0 (no) Kontrastmidler
ITPD20050018A1 (it) Composizione insetticida
DE502006002465D1 (de) Höhenverstellbarer Querträger
FI20055257A0 (fi) Luun proteiineja